|
|
LCP |
|
Vaxjo ID |
286 |
|
Vaccine Adjuvant Name |
LCP |
|
Adjuvant VO ID |
VO_0005736
|
|
Description |
lipid core peptide system that is a self adjuvanting delivery system, induces Th1 immune profile |
|
Stage of Development |
Research |
|
Components |
lipid section which mimics the PamCys system, and contains three fatty-acyl chains |
|
Structure |
Core: CaP/miRi complex → coated with lipid (DOPA) → embedded in PLGA-b-PEG matrix with paclitaxel; ~30–80 nm particles |
|
Preparation |
stepwise Boc solid-phase peptide synthesis |
|
Function |
Type: particulate antigen delivery system vaccine adjuvant. Target Receptor: Toll-like receptor 2 (TLR2). Induces Th1-biased immune profile. DC cell maturation |
| References |
Phillipps et al., 2009: Phillipps KS, Wykes MN, Liu XQ, Brown M, Blanchfield J, Toth I. A novel synthetic adjuvant enhances dendritic cell function. Immunology. 2009; 128(1 Suppl); e582-588. [PubMed: 19740319].
Skwarczynski and Toth, 2011: Skwarczynski M, Toth I. Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery. Methods in molecular biology (Clifton, N.J.). 2011; 751; 297-308. [PubMed: 21674338].
|
|
